Noriyo Nagata - Infectious Diseases

Author Information

Noriyo Nagata is a distinguished researcher affiliated with the Department of Pathology at the National Institute of Infectious Diseases in Tokyo, Japan. Her work primarily revolves around infectious diseases, with a specific focus on the immunological responses to coronaviruses, including SARS-CoV-2. Her research contributions have significantly advanced the understanding of viral pathogenesis and vaccine development.

Research Contributions

Noriyo Nagata has made substantial contributions to the field of infectious diseases, particularly in understanding the immune response to SARS-CoV-2. Her research includes the development of animal models for evaluating vaccine efficacy, the isolation of monoclonal antibodies with broad neutralizing activity against various SARS-CoV-2 variants, and the study of T cell responses in viral control. Her work is crucial for developing effective vaccines and therapeutic strategies against COVID-19 and other coronavirus infections.

Aliases

Noriyo Nagata is also known by the aliases N Nagata and N. Nagata in various publications and research databases.

Publication and Citation Metrics

Metric	Value
Total Papers	148
Total Citations	7752
h-index	42

Publications:

Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T cell responses

DOI: 10.1016/j.xcrm.2022.100520

Year: 2022

A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection.

DOI: 10.1126/sciadv.abh3827

Year: 2022

Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants

DOI: 10.1016/j.antiviral.2022.105297

Year: 2022

Broad Neutralization Activity of SARS-CoV-2 Antibody is Achieved by Coordinated Recognition of Virus Vulnerable Site

DOI: 10.2139/SSRN.3817803

Year: 2021

A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site

DOI: 10.1016/j.immuni.2021.08.025

Year: 2021

A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndrome

DOI: 10.1371/journal.ppat.1008859

Year: 2021

Immunotherapeutic Efficacy of IgY Antibodies Targeting the Full-Length Spike Protein in an Animal Model of Middle East Respiratory Syndrome Coronavirus Infection

DOI: 10.3390/ph14060511

Year: 2021

The peripheral T cell population is associated with pneumonia severity in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus 2

DOI: 10.1101/2021.01.07.425698

Year: 2021

Evaluation of serum antibodies against SARS-CoV-2 in healthcare workers who participated in the operation of charter flights for the evacuation of Japanese residents from Hubei Province

DOI: 10.1101/2021.03.17.21251964

Year: 2021

Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques

DOI: 10.1101/2021.05.26.445769

Year: 2021

How is Inherited Immunity Studied?

Are There Any Concerns About Drug Resistance?

What is Lipid Metabolism?

How Do RDTs Work?

What are the Technological Advances in Genomic Sequencing?

What Is the Relationship Between Climate Change and Food Security?

What are the Treatment Options for Infectious Diseases in Pregnancy?

Is there a Vaccine for West Nile Virus?

What is the Future of Vaccinations?

How Can One Access NIH Resources for Infectious Disease Research?

Partnered Content Networks

Relevant Topics